Table 4.
Patient's characteristics at time of KS diagnosis of KS cases occurred in patients on ART for more than 6 months between 2010 and 2015 in the French Dat'AIDS cohort according to HIV‐pVL > or ≤50 copies/mL
| Median [IQR] or N (%) | KS on ART† with HIV VL > 50 cp/mL n = 30 | KS on ART† with HIV VL ≤ 50 cp/mL n = 24 | P |
|---|---|---|---|
| Age (years) | 43.5 [36; 51.2] | 48.2 [39; 54.7] | 0.14 |
| Gender | |||
| Male | 26 (86.7) | 21 (87.5) | 1 |
| Female | 4 (13.3) | 3 (12.5) | |
| HIV Transmission group | |||
| MSM | 16 (53.3) | 14 (58.3) | 0.46 |
| Heterosexual | 7 (23.3) | 8 (33.3) | |
| IVDU | 2 (6.7) | 1 (4.2) | |
| Others/unknown | 5 (16.7) | 1 (4.2) | |
| HIV time follow‐up (y) | 12.8 [6.4; 15.8] | 7.4 [2.8; 20.7] | 0.21 |
| ≤1 | 0 | 3 (12.5) | 0.14 |
| [1–5] | 2 (6.7) | 5 (20.8) | |
| [5–10] | 11 (36.7) | 6 (25) | |
| [10–15] | 9 (30) | 4 (16.7) | |
| 15 | 8 (26.7) | 6 (25) | |
| Year of diagnosis | |||
| 2010 | 10 (33.3) | 1 (4.2) | |
| 2011 | 5 (16.7) | 5 (20.8) | 0.05a |
| 2012 | 5 (16.7) | 5 (20.8) | |
| 2013 | 1 (3.3) | 5 (20.8) | |
| 2014 | 6 (20) | 3 (12.5) | |
| 2015 | 3 (10) | 5 (20.8) | |
| Stage C at KS | |||
| Yes | 12 (42.9) | 7 (29.2) | 0.31 |
| No | 16 (57.1) | 17 (70.8) | |
| Nadir CD4/mm3 | 13 [5; 154] | 242 [120; 363] | <0.001 |
| <200/mm3 | 22 (75.9) | 9 (37.5) | 0.005 |
| CD4/mm3 | 69 [12; 301] | 467 [255; 819] | <0.001 |
| CD4 < 200/mm3 | 19 (63.3) | 4 (16.7) | 0.001 |
| CD4 > 500/mm3 | 1 (3.3) | 9 (37.5) | 0.003a |
| CD8/mm3 | 665 [507; 1321] | 960 [662; 1360] | 0.30 |
| CD8 ≥ 1000/mm3 | 9 (37.5) | 10 (41.7) | 0.77 |
| Ratio CD4 : CD8 | 0.2 [0; 0.3] | 0.5 [0.2; 0.9] | <0.001 |
| Ratio < 1 | 24 (100) | 18 (75) | 0.022a |
| HIV‐pVL (log/mL) | 3.4 [2.3; 4.9] | NA | |
| ART‐Time exposure (years) | 8 [3.9; 13.1] | 4.1 [1; 10.3] | 0.16 |
| ART initiation | |||
| Before 1995 | 2 (6.7) | 2 (8.3) | 0.30a |
| 1996–2006 | 15 (50) | 7 (29.2) | |
| ≥2007 | 13 (43.3) | 15 (62.5) | |
| Time exposure to the last ART (m) | 3.9 [0.9; 12.4] | 13.8 [7.6; 28.9] | 0.001 |
| Last ART | |||
| 2NRTI + 1bPI | 17 (56.7) | 8 (33.3) | 0.25a |
| 2NRTI + 1NNRTI | 2 (6.7) | 5 (20.8) | |
| 2NRTI + 1INSTI | 3 (10) | 2 (8.3) | |
| Others‡ | 8 (26.7) | 9 (37.5) | |
| KS Localizationb | |||
| Cutaneous | 20 (66.7) | 18 (75.0) | 0.57 |
| Oral mucosa/palate | 1 (3.3) | 2 (8.3) | |
| Bronchopulmonary | 4 (13.3) | 1 (4.2) | |
| Intestinal | 0 | 0 | |
| Lymph node | 2 (6.7) | 0 | |
| Disseminated | 0 | 0 | |
b, boosted; INSTI, integrase strand transfer inhibitor; NA, not applicable; NNRTI, non‐nucleoside reverse transcriptase inhibitor; NRTI, nucleotide reverse transcriptase inhibitor; PI, boosted protease inhibitor.
Fisher exact test.
For more than 6 months.
Others: 2NRTI + CCR5‐inhibitor: n = 1; bPI + INSTI: n = 2; bPI + CCR5‐inhibitor: n = 1; 1NRTI + 1bPI: n = 1; 2NRTI + 1bPI + 1INSTI: n = 2; 2NRTI + 1bPI + CCR5‐inhibitor: n = 1; 3NRTI + bPI: n = 1.
Data not available for 3 (10.0) patients with HIV‐pVL >50 cp/mL and for 3 (12.5) patients with HIV VL ≤50 cp/mL.